RGNT · Regentis Biomaterials Ltd. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-09 | Ben-Elazar Pini |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
This option grant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This option grant is fully vested as of this date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee. |
Employee Stock Option (Right to Buy)
|
8,313 |
| 2026-07-09 | Valentine Keith |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029. |
Employee Stock Option (Right to Buy)
|
24,826 |
| 2026-07-09 | Dykan Jeff |
Director |
Award↑
Filing footnotes — Warrants to purchase ordinary shares (Direct)
This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. The warrants are currently exercisable and have a three year term. |
Warrants to purchase ordinary shares
|
12,500 |
| 2026-07-09 | Cohen-Arazi Efraim |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029. . To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee. |
Employee Stock Option (Right to Buy)
|
24,826 |
| 2026-07-09 | Ben-Elazar Pini |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee. |
Employee Stock Option (Right to Buy)
|
24,826 |
| 2026-07-09 | Dykan Jeff |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee. |
Employee Stock Option (Right to Buy)
|
24,826 |
| 2026-07-09 | GELLER EHUD |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Warrants to purchase ordinary shares (Direct)
This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. The warrants are currently exercisable and have a three year term. |
Warrants to purchase ordinary shares
|
31,250 |
| 2026-07-09 | Alpert Susan PHD MD |
Director |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029. |
Employee Stock Option (Right to Buy)
|
24,826 |